EVROFConsumer Defensive · Packaged Foods · ΧΑ

Evrofarma

€3.65

+0.00(+0.00%)

Close 26/10/2026 · end-of-day price, not real-time

Evrofarma (EVROF) closed at €3.65 on 26/10/2026, +0.00% on the day. Market cap €49.8m, P/E 14.2, dividend yield 1.65%.

My view

Private · MENTOR takes it into account

−1.9%6M

Drag sideways across the chart to pick a period, or click an event's dot below it, then ask MENTOR about it.

26/10/2026Close 3.65+0.00%Vol 1.5k−1.9% since start

Key statistics

FY2025 unless a figure says otherwise

Profile

At the 26 Oct close

Market value: €49.8m
Enterprise valueDec 2025est.: €60.2m
Shares outstandingOct 2026: 13.6m
RevenueFY2025: €49.4m
Employees: 200
Free floatest.: 27.2%
Traded a day, 3-month average: €14.3k

Valuation

FY2025

P/E: 14.2×
P/B: 2.4×
EV/Salesest.: 1.2×
EV/EBITDAest.: 9.0×
P/FCF: —
Dividend yield: 1.6%

Margins

FY2025

Gross: 24.4%
EBITDA: 13.6%
Operating (EBIT): 10.6%
Pre-tax: 9.2%
Net: 7.1%
Free cash flow: −1.5%

Net margin = the shareholders' profit ÷ group revenue.

Returns

FY2025

ROE: 18.3%
ROCE: 16.8%
ROICest.: 13.1%
ROA: 6.3%
ROE, 5-year averageFY2021–25: 10.8%
Tax rate: 22.1%

Financial health

Dec 2025

Cash: €6.6m
Net debt: €10.4m
Net debt ÷ EBITDA: 1.5×
Debt ÷ equity: 82.6%
Interest coverFY2025: 7.5×

Growth

Revenue, last yearFY2025: +8.1%
EPS, last yearFY2025: +54.7%
Revenue, 3 yearsFY2022–25, a year: +2.9%
EPS, 3 yearsFY2022–25, a year: +35.4%

Dividends

FY2025

Yield, last 12 months: 1.6%
Per share: €0.060
Payout: 23.3%
Covered by free cash flow: −0.89×
Years paid, last fiveFY2021–25: 3

Trading and risk

From our closes, dividends reinvested

Total return, 1 year: +35.3%
3 years, a year: +63.6%
5 years, a year: +31.4%
10 years, a year: +32.4%
Volatility, 1 year: 32.5%
Beta to the General Index: 0.79×
Deepest fall, 1 year / 5 years: −20.0% / −47.1%
52-week range: €2.65–€4.31

est.worked out by us

Where the figures come from: the company's reports, reviewed by us · annual accounts filed in ESEF format · results announcements on the exchange · our own closing prices. No forecasts or target prices are stored.

Financial charts

From the stored figures: the reviewed dossier first, then the annual reports (ESEF) and results announcements

Loading the charts…

Valuation

vs KRI · all much larger

Metric	EVROF	KRI
P/E	14.2	—
P/B	2.4	—
P/S	1.0	3.5
EV/EBITDA	9.0	23.4
Dividend yield	1.6%	1.3%
Payout ratio	23.3%	—
Gross margin	24.4%	—
Operating margin	10.6%	—
Net margin	7.1%	10.4%
ROE	18.3%	—
Revenue growth (last full year)	8.1%	28.2%
Net debt	€10.4m	−€8.3m

Twelve Data · latest quarter 31/12/2025

Peers: Dairy

EV/EBITDADay

Kri-Kri Milk IndustryKRI23.4+0.3%

EvrofarmaEVROF9.0+0.0%

Loulis Food IngredientsKYLO5.9+2.4%

MediterraMASTIHA13.8—

Flour Mills C. SarantopoulosKYSA50.0—

Compare in depth

The company

AI-drafted

Evrofarma produces milk, yogurt and cheese in Thrace for Greece and export markets. Wholly owned Campus raises cattle and produces milk. The group combines farming and processing, with substantial exposure to one large customer.

How it makes moneyH1 2026 · basis: revenue

Dairy production and sales¹⁰(External segment sales, share of €26.470m calculated.)95.4%
Milk production and cattle rearing¹⁰(Campus external sales; intersegment sales to the parent are excluded.)4.6%

It is

An integrated dairy group with cattle-farming operations.^1,8
A family-controlled company with ordinary shares on the Athens exchange.^1,9

It is not

It is not exclusively a yogurt exporter.¹
The share is not a direct interest in a separately listed Campus.^1,8

Recent developmentsAll company events →

Sep 2026H1 2026 results were published: revenue €26.470m (+8.8%), EBITDA €4.833m (+44.3%).^10,11
Sep 2026The FY2025 dividend was set at €0.0601276633 gross per eligible share, with payment starting September 22.^4,12
Sep 2026A new seven-member board with three independent members and an auditor for FY2026 were elected.^3,5
Aug 2026Treasury shares reached 29,031, or 0.2123% of issued capital.⁶
May 2026The €7.2m Green Transition investment programme, mainly for strained yogurt, was completed.^2,10,11
Nov 2025A programme to acquire up to 683,660 treasury shares began, running through August 5 2027.⁷

Key figures

Group revenue €26.470m H1 2026¹⁰
Profit attributable to parent shareholders €2.608m H1 2026¹⁰
Net bank debt, excluding leases €12.278m 2026-06-30¹⁰
Consolidated equity €23.239m 2026-06-30¹⁰
Largest customer share of revenue 56% H1 2026¹⁰

Key facts

The group employed 200 people at June 30 2026.¹⁰
The new board took office on September 4 2026, with Panagiotis Papazilakis as chair; Orion was elected auditor for FY2026.^3,5
In H1 2026 operating cash flow was €4.283m and fixed-asset purchases €6.242m, with no grants received.¹⁰
The FY2025 dividend was €0.0601276633 gross per eligible share, with payment starting September 22 2026.^4,12

Sources

1.Annual financial report FY2025Evrofarma S.A. · 17/04/2026official
2.FY2025 results release EnglishEvrofarma S.A. · 17/04/2026official
3.New board and committees corrected notice dated September 4, republished September 7Evrofarma S.A. · 07/09/2026official
4.FY2025 dividend corrected notice dated September 4, republished September 7Evrofarma S.A. · 07/09/2026official
5.Annual general meeting decisions September 4 2026Evrofarma S.A. · 04/09/2026official
6.Treasury shares held after August 21 purchasesEvrofarma S.A. · 21/08/2026official
7.Launch of treasury share programmeEvrofarma S.A. · 10/11/2025official
8.Campus standalone annual financial report FY2025Evrofarma S.A.official
9.ESMA FIRDS current XATH instrument recordESMAofficial
10.Half-year report H1 2026Evrofarma S.A. · 25/09/2026official
11.H1 2026 results release EnglishEvrofarma S.A. · 25/09/2026official
12.Cash-distribution historyEuronext Athensofficial

AI-drafted from the cited sources · 23/10/2026 · v2 · ✓ checked by an independent second modelEvrofarma S.A.Website ↗

MENTORAsk MENTOR about EvrofarmaFree beta

Why it moved

Flat · volume 0.4×

News & events

News and what's next

Peers

No listed peers

Results

How it did vs last year

Valuation

No listed peers

Asks“What's the latest news on Evrofarma, and what's coming up?”

Data: Twelve Data · End-of-day prices · Nothing here is investment advice.